{"id":1389,"date":"2026-09-10T22:46:43","date_gmt":"2026-09-10T14:46:43","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=1389"},"modified":"2026-09-10T22:46:43","modified_gmt":"2026-09-10T14:46:43","slug":"nanoactive-r-retinoate-3","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=1389","title":{"rendered":"NanoActive™ r-Retinoate"},"content":{"rendered":"

NanoActive™ r-Retinoate<\/h2>\n

A new-generation, high-performance vitamin A active<\/p>\n\n\n\n
8\u00d7RETINOL POWERHigh efficacy at low concentration \u00b7 High stability \u00b7 Potential for high tolerabilityA new-generation hybrid retinoid<\/td>\nINCI Retinyl Retinoate<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

PuriPharm Co. Ltd.<\/p>\n

Source\uff1a<\/b>Structure: PubChem CID 10303376. The 8\u00d7 claim refers only to the low-concentration in vitro collagen synthesis experiment detailed in \u201c8\u00d7 Retinol-Level Collagen Performance.\u201d<\/p>\n

01 MOLECULAR DESIGN<\/p>\n

The traditional vitamin A trade-off<\/h2>\n

Traditional vitamin A actives rarely combine activity, stability, and tolerability<\/p>\n\n\n\n\n\n\n
Retinoid<\/th>\nCore attribute<\/th>\nKey limitation<\/th>\n<\/tr>\n
Retinoic Acid<\/td>\nHigh activity<\/td>\nHigher irritation potential and greater restrictions on use<\/td>\n<\/tr>\n
Retinol<\/td>\nGold standard<\/td>\nSensitive to light, heat, oxygen, and other factors<\/td>\n<\/tr>\n
Retinyl Esters<\/td>\nHigh stability<\/td>\nUsually lower biological activity<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

High activity + High stability + High tolerability<\/p>\n

What if one vitamin A molecule could offer all three?<\/p>\n

Next: the hybrid retinoid architecture<\/p>\n

Source\uff1a<\/b>Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005.<\/p>\n

01 MOLECULAR DESIGN<\/p>\n

Hybrid Retinoid molecular architecture<\/h2>\n

One molecule combines the structural logic of two classic retinoids<\/p>\n

RETINOL + RETINOIC ACID<\/p>\n

Esterification forms RETINYL RETINOATE<\/p>\n

<\/p>\n\n\n\n\n\n\n
No.<\/th>\nDesign logic<\/th>\n<\/tr>\n
01<\/td>\nBlock the Retinoic Acid carboxyl group<\/td>\n<\/tr>\n
02<\/td>\nPreserve the key retinoid ring structure and polyene chain<\/td>\n<\/tr>\n
03<\/td>\nRebalance activity, stability, and tolerability<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Source\uff1a<\/b>Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005. Structure: PubChem CID 10303376.<\/p>\n

01 MOLECULAR DESIGN<\/p>\n

NanoActive™ r-Retinoate \u00b7 Product overview<\/h2>\n

Core molecular information and market positioning<\/p>\n\n\n\n\n\n\n\n\n
Item<\/th>\nInformation<\/th>\n<\/tr>\n
Product<\/td>\nNanoActive™ r-Retinoate<\/td>\n<\/tr>\n
INCI name<\/td>\nRetinyl Retinoate<\/td>\n<\/tr>\n
Category<\/td>\nHybrid RetinoidVitamin A derivativeAnti-aging active<\/td>\n<\/tr>\n
Molecular data<\/td>\nFormula C\u2084\u2080H\u2085\u2086O\u2082Molecular weight 568.87CAS 15498-86-9<\/td>\n<\/tr>\n
Absorption maximum<\/td>\n\u03bbmax 333 nm; Retinol 323 nm<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

8\u00d7 Retinol collagen performancePhotostable retinoidImproved thermal stabilityDirect retinoid bioactivityHyaluronan boostHigh efficacy at low concentrationSkin and scalp applicationsCompatible with nano-delivery<\/p>\n

Source\uff1a<\/b>PubChem CID 10303376; Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005. Appearance, active content, particle size, PDI, carrier composition, recommended use level, pH, addition temperature, and storage conditions must follow the latest PuriPharm TDS \/ SPEC \/ COA.<\/p>\n

02 COLLAGEN PERFORMANCE<\/p>\n

8\u00d7 Retinol-level collagen performance<\/h2>\n

Approximately eight times the collagen synthesis response of Retinol at low concentration<\/p>\n\n\n\n
8\u00d7Collagen biosynthesis at low concentration41.29% \u00f7 4.94% \u2248 8.36\u00d7<\/td>\nRetinol+4.94%Retinyl Retinoate+41.29%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Test concentration:<\/b> 10\u207b\u2076% (w\/v)<\/p>\n

Lower concentration, more collagen<\/p>\n

Source\uff1a<\/b>*In an in vitro collagen synthesis experiment at 10\u207b\u2076% (w\/v), Retinyl Retinoate increased collagen synthesis by 41.29%, versus 4.94% with Retinol, equivalent to approximately 8.36\u00d7. US7173062B2, \u201cMethod for the Improvement of Skin Wrinkles Using Retinyl Retinoate.\u201d See also Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005.<\/p>\n

02 COLLAGEN PERFORMANCE<\/p>\n

Lower concentration, more collagen<\/h2>\n

Retinyl Retinoate shows strong collagen synthesis performance even at low concentrations<\/p>\n\n\n\n\n\n\n
Concentration<\/th>\nRetinoic Acid<\/th>\nRetinol<\/th>\nRetinyl Palmitate<\/th>\nRetinyl Retinoate<\/th>\n<\/tr>\n
0.1 \u03bcM<\/td>\n1%<\/td>\n\u2014<\/td>\n\u2014<\/td>\n1.5%<\/td>\n<\/tr>\n
1 \u03bcM<\/td>\n14%<\/td>\n10%<\/td>\n2%<\/td>\n14%<\/td>\n<\/tr>\n
10 \u03bcM<\/td>\n52%<\/td>\n42%<\/td>\n14%<\/td>\n48%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

High efficacy at low concentration<\/p>\n

Outperforms Retinol in the low-concentration range and approaches Retinoic Acid at some concentrations<\/p>\n

Metric: increase in collagen synthesis (%)<\/p>\n

Source\uff1a<\/b>Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005. Redrawn from Figure 6. Bar values are visual readings from the axes and preserve the trend reported in the article.<\/p>\n

02 COLLAGEN PERFORMANCE<\/p>\n

A retinoid with direct biological activity<\/h2>\n

The molecule can display retinoid activity without first undergoing complete hydrolysis<\/p>\n\n\n\n\n\n
Route<\/th>\nSequence<\/th>\nInterpretation<\/th>\n<\/tr>\n
Traditional Retinyl Ester<\/td>\nRetinyl Ester \u2192 Retinol \u2192 Retinal \u2192 Retinoic Acid \u2192 RAR<\/td>\nRequires multiple conversion steps before entering RAR signaling<\/td>\n<\/tr>\n
Retinyl Retinoate<\/td>\nRetinyl Retinoate \u2192 observed biological effect<\/td>\nDirect retinoid activity<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

HPLC evidence<\/p>\n

After two days of incubation with normal human skin fibroblasts, HPLC detected no new peaks corresponding to Retinol or Retinoic Acid.<\/p>\n

The authors therefore attributed the observed biological activity to the molecule itself rather than simple hydrolysis.<\/p>\n

Not an ordinary retinyl ester<\/p>\n

Source\uff1a<\/b>Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005.<\/p>\n

02 COLLAGEN PERFORMANCE<\/p>\n

Promotes synthesis and limits degradation<\/h2>\n

Bidirectional collagen management through RAR, AP-1, and collagen signaling<\/p>\n\n\n\n\n\n\n
Photoaging cascade<\/th>\nDirection associated with NanoActive™ r-Retinoate<\/th>\n<\/tr>\n
UV \/ environmental stress \u2192 c-Jun \/ AP-1 \u2191 \u2192 collagenase \/ MMP \u2191 \u2192 collagen degradation \u2192 wrinkles<\/td>\nRetinoid signaling \/ RAR \u2192 AP-1 \/ c-Jun \u2193<\/td>\n<\/tr>\n
Collagen degradation<\/td>\nPromotes synthesis: Collagen Biosynthesis \u2191<\/td>\n<\/tr>\n
Increased collagenase \/ MMP<\/td>\nReduces degradation signals: Collagenase \/ MMP \u2193<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

52%<\/p>\n

Collagenase inhibition<\/p>\n

Retinyl Retinoate > Retinol<\/p>\n

Source\uff1a<\/b>Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005. With RAR\u03b1 expression, collagenase expression was inhibited by approximately 33% with Retinol, 52% with Retinyl Retinoate, and 64% with Retinoic Acid; also supported by US7173062B2, \u201cMethod for the Improvement of Skin Wrinkles Using Retinyl Retinoate.\u201d<\/p>\n

03 STABILITY & TOLERABILITY<\/p>\n

Designed for photostability<\/h2>\n

Retinoid performance that withstands light exposure<\/p>\n

48 h<\/p>\n

UVA photostability<\/p>\n

The main structure retained markedly greater stability even after 48 hours of UVA exposure.<\/p>\n

UVA:<\/b> 356 nm; observations at 2, 12, 24, and 48 hours<\/p>\n\n\n\n\n\n
Compound<\/th>\n0 h<\/th>\n2 h<\/th>\n12 h<\/th>\n24 h<\/th>\n48 h<\/th>\n<\/tr>\n
Retinyl Retinoate<\/td>\nBaseline<\/td>\nStable<\/td>\nStable<\/td>\nStable<\/td>\nOnly minor noise \/ no qualitative change<\/td>\n<\/tr>\n
Retinol<\/td>\nBaseline<\/td>\nClear degradation<\/td>\nNo longer reliably identified qualitatively<\/td>\nNo longer reliably identified qualitatively<\/td>\nNo longer reliably identified qualitatively<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u03bbmax: Retinol 323 nm; Retinyl Retinoate 333 nm<\/p>\n

Source\uff1a<\/b>Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005.; US7173062B2, \u201cMethod for the Improvement of Skin Wrinkles Using Retinyl Retinoate.\u201d Photostability experiment: UVA 356 nm and qualitative \u00b9H NMR. \u201c48 h\u201d is the study duration, not a direct quantitative claim of percentage remaining.<\/p>\n

03 STABILITY & TOLERABILITY<\/p>\n

Stability beyond light exposure<\/h2>\n

Thermal stability was clearly better than Retinol after four weeks under accelerated conditions<\/p>\n\n\n\n\n\n\n
Four-week condition<\/th>\nRetinol remaining<\/th>\nRetinyl Retinoate remaining<\/th>\n<\/tr>\n
Room temperature<\/td>\n52.23%<\/td>\n89.21%<\/td>\n<\/tr>\n
40\u00b0C<\/td>\n34.51%<\/td>\n68.23%<\/td>\n<\/tr>\n
4\u00b0C<\/td>\n95.52%<\/td>\n99.65%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Improved thermal stabilityMore robust formulationsMore reliable retinoid performance<\/p>\n

Source\uff1a<\/b>US7173062B2, \u201cMethod for the Improvement of Skin Wrinkles Using Retinyl Retinoate.\u201d Thermal stability experiment: HPLC quantification after four weeks at room temperature, 40\u00b0C, and 4\u00b0C.<\/p>\n

03 STABILITY & TOLERABILITY<\/p>\n

High performance with greater mildness<\/h2>\n

A wider cellular tolerance window and evidence from a human occlusive patch test<\/p>\n\n\n\n\n
In vitro MTT<\/th>\nIC\u2085\u2080<\/th>\n<\/tr>\n
+60%IC\u2085\u2080 versus RetinolLower cytotoxicity in this in vitro model<\/td>\nIn vitro MTTIC\u2085\u2080Retinol25 \u03bcMRetinyl Retinoate40 \u03bcM<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
24 h human occlusive patch test<\/th>\nConcentration<\/th>\nIrritation index; lower is better<\/th>\n<\/tr>\n
Retinol<\/td>\n0.075%<\/td>\n2.5<\/td>\n<\/tr>\n
r-Retinoate<\/td>\n0.075%<\/td>\n1.3<\/td>\n<\/tr>\n
r-Retinoate<\/td>\n0.30%<\/td>\n1.3<\/td>\n<\/tr>\n
r-Retinoate<\/td>\n0.55%<\/td>\n1.3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

High performance and low irritation in the same profile<\/p>\n

Source\uff1a<\/b>Kim H, Kim B, Kim H, et al. \u201cSynthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative.\u201d Bioorganic & Medicinal Chemistry<\/i>. 2008;16(12):6387\u20136393. DOI: 10.1016\/j.bmc.2008.05.005. Normal human skin fibroblast MTT assay: IC\u2085\u2080 40 \u03bcM versus 25 \u03bcM for Retinol. Human occlusive patch data: US7173062B2, \u201cMethod for the Improvement of Skin Wrinkles Using Retinyl Retinoate.\u201d<\/p>\n

04 BEYOND COLLAGEN<\/p>\n

7.8\u00d7 hyaluronan production<\/h2>\n

Extending from wrinkle care to hydration, plumpness, and barrier support<\/p>\n

7.8\u00d7<\/p>\n

Hyaluronan production<\/p>\n

Primary human keratinocytes; 1 \u03bcM \/ 24 hRetinaldehyde \u2248 7.6\u00d7 control<\/p>\n\n\n\n\n\n
Mechanistic path<\/th>\nOutcome<\/th>\n<\/tr>\n
Retinyl Retinoate \u2192 HAS2 \u2191<\/td>\nHyaluronan \u2191<\/td>\n<\/tr>\n
Hyaluronan \u2191 \u2192 CD44 interaction<\/td>\nHydration \u00b7 ECM support \u00b7 Homeostasis<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Retinyl Retinoate upregulated HAS2 and increased CD44-related expression.<\/p>\n

Source\uff1a<\/b>Kim JE, Kim B, Kim H, et al. \u201cRetinyl retinoate induces hyaluronan production and less irritation than other retinoids.\u201d Journal of Dermatology<\/i>. 2010;37(5):448\u2013454. DOI: 10.1111\/j.1346-8138.2010.00808.x. In primary human keratinocytes, Retinyl Retinoate at 1 \u03bcM for 24 h induced hyaluronan production to approximately 7.8 times the control level.<\/p>\n

04 BEYOND COLLAGEN<\/p>\n

High activity with less barrier disruption<\/h2>\n

Lower TEWL impact at the same 0.05% concentration<\/p>\n\n\n\n\n\n\n\n
Retinoid<\/th>\nRelative TEWL \/ barrier disruption ranking<\/th>\n<\/tr>\n
Retinyl Retinoate<\/td>\nLowest<\/td>\n<\/tr>\n
Retinol<\/td>\nLow<\/td>\n<\/tr>\n
Retinoic Acid<\/td>\nHigh<\/td>\n<\/tr>\n
Retinaldehyde<\/td>\nHigh<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

7.8\u00d7 hyaluronan production + lower TEWL disruption<\/p>\n

A better balance of efficacy and tolerability<\/p>\n

Source\uff1a<\/b>Kim JE, Kim B, Kim H, et al. \u201cRetinyl retinoate induces hyaluronan production and less irritation than other retinoids.\u201d Journal of Dermatology<\/i>. 2010;37(5):448\u2013454. DOI: 10.1111\/j.1346-8138.2010.00808.x. Hairless-mouse TEWL model with 0.05% comparative application. The ranking redraws the irritation order reported in the article.<\/p>\n

05 CLINICAL EVIDENCE<\/p>\n

Human evidence with a Retinol comparator<\/h2>\n

Uncommon direct human comparison against Retinol<\/p>\n\n\n\n
0.06%Retinyl RetinoateSignificantly better than 0.075% Retinol<\/td>\n46Korean women \u00b7 Periorbital wrinklesTwo randomized clinical studies<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n
Study<\/th>\nDuration and completers<\/th>\nIntervention<\/th>\nFrequency<\/th>\n<\/tr>\n
Study 1<\/td>\n12 weeks; 24 completed<\/td>\n0.06% Retinyl Retinoate versus placebo<\/td>\nTwice daily<\/td>\n<\/tr>\n
Study 2<\/td>\n8 weeks; 22 completed<\/td>\n0.06% Retinyl Retinoate versus 0.075% Retinol<\/td>\nTwice daily<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Assessments:<\/b> global photoaging score \u00b7 photographs \u00b7 skin replicas \u00b7 Visiometer<\/p>\n

Wrinkles improved significantly with Retinyl Retinoate versus placebo and Retinol.<\/p>\n

Source\uff1a<\/b>Kim H, Kim N, Jung S, et al. \u201cImprovement in skin wrinkles from the use of photostable retinyl retinoate: a randomized controlled trial.\u201d British Journal of Dermatology<\/i>. 2010;162(3):497\u2013502. DOI: 10.1111\/j.1365-2133.2009.09483.x. Skin-replica analysis showed significant improvement, particularly in mean roughness.<\/p>\n

05 CLINICAL EVIDENCE<\/p>\n

22% greater improvement in maximum roughness<\/h2>\n

A 12-week double-blind randomized comparison versus 0.075% Retinol<\/p>\n\n\n\n\n
Study design<\/th>\nInformation<\/th>\n<\/tr>\n
+22%R2 maximum roughnessImprovement rate versus Retinol<\/td>\nStudy designInformationDesignProspective \u00b7 Double-blind \u00b7 Randomized \u00b7 ControlledParticipants11 Korean women; 35\u201356 yearsDuration \/ frequency12 weeks; twice dailyComparison0.06% Retinyl Retinoate versus 0.075% RetinolAnalysisVisiometer R2; 12-week head-to-head comparison<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Validated dimensions:<\/b> fine-line reduction, elasticity, visual wrinkle grade, skin roughness, and dermal distance \/ intensity.<\/p>\n

Source\uff1a<\/b>Kim H, Koh J, Baek J, et al. \u201cRetinyl retinoate, a novel hybrid vitamin derivative, improves photoaged skin: a double-blind, randomized-controlled trial.\u201d Skin Research and Technology<\/i>. 2011;17(3):380\u2013385. DOI: 10.1111\/j.1600-0846.2011.00512.x. At 12 weeks, the improvement rates for visual wrinkles and R2 maximum roughness were 22% higher than with Retinol.<\/p>\n

05 CLINICAL EVIDENCE<\/p>\n

Beyond anti-aging<\/h2>\n

Retinoid science for blemish-prone and oily skin<\/p>\n

Protocol:<\/b> 0.05% Retinyl Retinoate \u00b7 8 weeks \u00b7 double-blind \u00b7 vehicle-controlled \u00b7 split-face; 15 women with mild-to-moderate acne.<\/p>\n\n\n\n\n\n\n
Eight-week outcome<\/th>\nVehicle<\/th>\nRetinyl Retinoate<\/th>\n<\/tr>\n
Total lesion count<\/td>\n\u221226.47%<\/td>\n\u221238.58%<\/td>\n<\/tr>\n
Inflammatory lesions<\/td>\n\u221235.14%<\/td>\n\u221243.62%<\/td>\n<\/tr>\n
Non-inflammatory lesions<\/td>\n\u221219.79%<\/td>\n\u221233.98%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u221227.18%<\/p>\n

Forehead sebum<\/p>\n

Baseline 104.86 \u03bcg\/cm\u00b2; week 8: 76.36 \u03bcg\/cm\u00b2<\/p>\n

Blemish-prone skin careSebum balanceFollicular keratinization careClearer-looking skin<\/p>\n

Source\uff1a<\/b>Kim B, et al. \u201cRetinyl Retinoate, a Retinoid Derivative Improves Acne Vulgaris in Double-blind, Vehicle-controlled Clinical Study.\u201d Tissue Engineering and Regenerative Medicine<\/i>. 2013;10(5):260\u2013265. DOI: 10.1007\/s13770-012-1088-z. Percentages are reductions in lesion counts after eight weeks; the change in sebum was statistically significant.<\/p>\n

06 DELIVERY PLATFORM<\/p>\n

Molecule \u00d7 nano-delivery<\/h2>\n

Unlocking the full potential of r-Retinoate<\/p>\n

Retinyl Retinoate is highly lipophilic, so formulation must solve several engineering challenges:<\/b><\/p>\n

01 Dispersibility02 Stability03 Drug loading04 Skin delivery05 Controlled release<\/p>\n

RETINYL RETINOATE + Nano-delivery<\/p>\n

A performance-optimized retinoid delivery system<\/p>\n\n\n\n\n\n\n\n
Published NLC feasibility evidence<\/th>\nValue<\/th>\n<\/tr>\n
Particle size<\/td>\n230\u2013300 nm<\/td>\n<\/tr>\n
PDI<\/td>\nNo value listed in the source slide<\/td>\n<\/tr>\n
PRECIROL-NLC encapsulation efficiency<\/td>\n97.8%<\/td>\n<\/tr>\n
COMPRITOL-NLC encapsulation efficiency<\/td>\n93.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

These values describe a published NLC system and are not specifications for NanoActive™ r-Retinoate.<\/p>\n

Source\uff1a<\/b>Lee SG, Jeong JH, Kim SR, et al. \u201cTopical formulation of retinyl retinoate employing nanostructured lipid carriers.\u201d Journal of Pharmaceutical Investigation<\/i>. 2012;42(5):243\u2013250. DOI: 10.1007\/s40005-012-0036-1. Particle size, PDI, encapsulation efficiency, and carrier parameters for NanoActive™ itself must follow authentic PuriPharm TDS \/ SPEC \/ COA documents.<\/p>\n

06 DELIVERY PLATFORM<\/p>\n

Encapsulation amplifies delivery performance<\/h2>\n

Independent research shows that advanced delivery can further enhance Retinyl Retinoate<\/p>\n\n\n\n\n\n
Form<\/th>\nExposure \/ penetration<\/th>\nDelivery performance<\/th>\n<\/tr>\n
Free RR<\/td>\nConventional exposure; limited penetration<\/td>\n\u2014<\/td>\n<\/tr>\n
Encapsulated RR<\/td>\nImproved penetration<\/td>\nMore efficient delivery; enhanced anti-wrinkle performance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Encapsulation \u2192 Improved penetration \u2192 More efficient delivery \u2192 Enhanced anti-wrinkle performance<\/p>\n\n\n\n
+6.05%Visual wrinkle improvement<\/td>\n+8.03%R2 maximum roughness<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Source\uff1a<\/b>Kim H, et al. \u201cNovel anti-wrinkle effect of cosmeceutical product with new retinyl retinoate microsphere using biodegradable polymer.\u201d Skin Research and Technology<\/i>. 2012;18(1):70\u201376. DOI: 10.1111\/j.1600-0846.2011.00533.x. Outcomes compare a 3% PLA\u2013retinyl retinoate (2%) microsphere cream with a 0.06% Retinyl Retinoate cream over four weeks. Published PLA microsphere evidence does not represent NanoActive™ technology.<\/p>\n

07 APPLICATIONS<\/p>\n

From face to scalp<\/h2>\n

Advanced retinoid science for scalp care<\/p>\n\n\n\n
SkinWrinkle careCollagen renewalHyaluronan boostFirmingRefined texturePhotoaging careBlemish-prone skinSebum balance<\/td>\nScalpScalp renewalSebum balanceFollicular keratinization careScalp anti-agingPilosebaceous unit careHealthy follicular environment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Retinoid signaling is present in hair follicles, sebaceous glands, and interfollicular epidermis, and participates in epithelial differentiation, sebaceous biology, and follicular keratinization.<\/p>\n

Source\uff1a<\/b>Mechanistic background: Everts HB, Sundberg JP, King LE Jr, Ong DE. \u201cImmunolocalization of enzymes, binding proteins, and receptors sufficient for retinoic acid synthesis and signaling during the hair cycle.\u201d Journal of Investigative Dermatology<\/i>. 2007;127(7):1593\u20131604. DOI: 10.1038\/sj.jid.5700753. Scalp positioning covers scalp health, anti-aging, oil control, and support for the follicular environment. No direct hair-growth claim should be made without product-specific clinical evidence.<\/p>\n

07 APPLICATIONS<\/p>\n

One retinoid, multiple performance dimensions<\/h2>\n

Eight efficacy dimensions create a complete premium active platform<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
No.<\/th>\nPerformance dimension<\/th>\n<\/tr>\n
01<\/td>\n8\u00d7 Collagen Performance<\/td>\n<\/tr>\n
02<\/td>\nWrinkle Reduction<\/td>\n<\/tr>\n
03<\/td>\nPhotostability<\/td>\n<\/tr>\n
04<\/td>\nThermal Stability<\/td>\n<\/tr>\n
05<\/td>\nHyaluronan Boost<\/td>\n<\/tr>\n
06<\/td>\nBetter Tolerance<\/td>\n<\/tr>\n
07<\/td>\nBlemish & Sebum Care<\/td>\n<\/tr>\n
08<\/td>\nScalp Renewal<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Source\uff1a<\/b>The efficacy dimensions summarize the preceding evidence. Each quantitative claim retains its experimental model, comparator, concentration, and source in the corresponding section.<\/p>\n

07 APPLICATIONS<\/p>\n

Designed for the next generation of beauty innovation<\/h2>\n

Premium dual applications across skin and scalp<\/p>\n\n\n\n
Skin carePremium anti-aging serumLine-smoothing serumEye serum \/ eye creamNight repairDay-and-night retinoid productsPhotoaging careFirming and elasticity productsHydrating anti-aging productsBlemish-prone skin careOily-skin serum<\/td>\nScalp and hair careScalp anti-aging essenceScalp anti-aging serumScalp renewal serumOily-scalp serumFollicular environment careLeave-on scalp carePremium scalp ampoule<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Formats:<\/b> serum \u00b7 cream \u00b7 lotion \u00b7 ampoule \u00b7 eye care \u00b7 scalp serum \u00b7 leave-on care<\/p>\n

Source\uff1a<\/b>Application guidance is conceptual and based on published Retinyl Retinoate evidence. Recommended use level, pH, addition temperature, solubility, compatibility, storage conditions, and finished-product stability for NanoActive™ r-Retinoate must follow official PuriPharm TDS \/ SPEC \/ COA documents. No product-specific parameters are inferred here.<\/p>\n

CLOSING<\/p>\n

NanoActive™ r-Retinoate<\/h2>\n

Higher performance at a lower concentration. Redefining next-generation vitamin A anti-aging technology.<\/p>\n

8\u00d7 collagen performancePhotostabilityClinically evaluatedHyaluronan boostNano-delivery<\/p>\n

A new-generation, high-performance vitamin A active<\/p>\n

PuriPharm Co. Ltd.<\/p>\n

Source\uff1a<\/b>*\u201c8\u00d7 Retinol Power\u201d is a marketing shorthand for an approximately 8.36-fold difference in low-concentration in vitro collagen synthesis performance: 41.29% versus 4.94% at 10\u207b\u2076% w\/v. Source: US7173062B2. It does not mean 8\u00d7 RAR activation, 8\u00d7 human wrinkle reduction, 8\u00d7 lower irritation, or 8\u00d7 performance across all biological endpoints.<\/p>\n","protected":false},"excerpt":{"rendered":"

NanoActive™ r-Retinoate A new-generation, high-p […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[32,34],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1389"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1389"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1389\/revisions"}],"predecessor-version":[{"id":1390,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1389\/revisions\/1390"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1389"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}